Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Jazz Pharmaceuticals has agreed to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent milestone payments. The transaction centers on ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy, an ultra-rare disease affecting approximately 2,500 patients in the U.S. with no approved therapies.
Key figures
- Drug Name
- ABS-1230
- Deal Value Usd
- 820000000
- Phase Of Trial
- Phase 1b/2a
- Contingent payment
- 500000000
- Patient population
- 2500
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.